Psychedelic Spotlight Interview with Joshua White

Today we are going to be talking about MindMed’s, (MNDM : NASDAQ), (MMED : NEO) patent application made in collaboration with BioXcel Therapeutics.
BioXcel is a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology.
The Patent is “for detecting and preventing the early onset of agitation in patients predisposed to highly agitated behaviour”.

Enjoy the episode!

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#mindmed #mmed #mnmdstock

MindMed Changes CEO? Hey Guys! What a day it has been! Today, MindMed (MMED :NEO),
(MNMD: NASDAQ), and (MMQ: FRA) has announced that JR Rahn has stepped down as CEO of MindMed effective immediately. Chief Development Officer, Robert Barrow will assume the role while MindMed is considering possible candidates.

In this episode, we’ll cover several things.

1.What happened?
2.My general thoughts on the leadership change.
3.My thoughts on JR Rahn’s successes and his departure.
4.What Robert Barrow brings to the table as CEO.

Links:
MindMed changes leadership:
https://mindmed.co/news/press-release/mindmed-announces-chief-executive-officer-transition/

Robert Barrow background:
https://mindmed.co/team/robert-barrow-1/
https://www.newswire.ca/news-releases/mindmed-adds-chief-development-officer-with-fda-phase-2-psilocybin-clinical-trial-experience-862550304.html

General Reddit sentiment about MindMed’s leadership change:
https://www.reddit.com/r/MindMedInvestorsClub/comments/nvwtou/expected_this_sub_to_be_on_fire_this_morning_but/

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @thepsychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
Video editing: @themyaholy
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #MNMD #MindmedNews